Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Paola Magnaghi et al.|Molecular Cancer Therapeutics|2016Cited by 317
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Laura Raddrizzani et al.|Molecular Oncology|2014Cited by 156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase InhibitorMaria Gabriella Brasca, Marina Ciomei, Achille Panzeri et al.|Journal of Medicinal Chemistry|2009Cited by 128
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and BrachyuryPaola Magnaghi, Antonella Isacchi, Barbara Salom et al.|Molecular Cancer Therapeutics|2017Cited by 93
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Molecular Cancer Therapeutics|2010Cited by 63